Referencer - Region Nordjylland



ReferencerCunha BA, Quintiliani R, Deglin JM, Izard MW, Nightingale CH. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis. 1981; 3 suppl:S269-72.Davis SL, Scheetz MH, Bosso JA, Goff DA, Rybak MJ. Adherence to the 2009 Consensus Guidelines for Vancomycin Dosing and Monitoring Practices: A Cross-Sectional Survey of U.S. Hospitals. Pharmacotherapy. 2013 Jul 29. doi: 10.1002/phar.1327. [Epub ahead of print] Follin SL, Mueller BA, Scott MK, Carfagna MA, Kraus MA. Falsely elevated serum vancomycin concentrations in hemodialysis patients. Am J Kidney Dis. 1996; 27(1):67-74.Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012; 32(3):195-201. Erratum in: Pharmacotherapy. 2012; 32(9):869.Legal M, Wan M. Influence of age on frequency of vancomycin dosing. Can J Hosp Pharm. 2010; 63(1):13-9.Leu WJ, Liu YC, Wang HW, Chien HY, Liu HP, Lin YM. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. Int J Infect Dis. 2012; 16(11):e804-10. doi:10.1016/j.ijid.2012.07.005.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52(3):e18-55. doi: 10.1093/cid/ciq146. Erratum in: Clin Infect Dis. 2011; 53(3):319.Mizokami F, Shibasaki M, Yoshizue Y, Noro T, Mizuno T, Furuta K. Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging. 2013;8:1015-21.Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin troughs adequate for optimal dosing? Antimicrob Agents Chemother. 2013 Oct 28. [Epub ahead of print]. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009; 29(11):1275-9. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009; 49(3):325-7. Erratum in: Clin Infect Dis. 2009 Nov 1;49(9):1465. R?det for Anvendelse af Dyr Sygehusmedicin. L?gemiddelrekommandationer for systemisk antimykotisk behandling. 2012.Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, Thom KA, Cosgrove SE, Sakoulas G, Perencevich EN. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011; 11:279.Thalakada R, Legal M, Lau TT, Luey T, Batterink J, Ensom MH. Development and validation of a novel vancomycin dosing nomogram for achieving high-target trough levels at 2 canadian teaching hospitals. Can J Hosp Pharm. 2012; 65(3):180-7. Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J. 2012; 42(1):23-9.van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013 Feb;57(2):734-44. Vandecasteele SJ, De Vriese AS, Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother. 2013; 68(4):743-8. Vandecasteele SJ, De Vriese AS. Vancomycin dosing in patients on intermittent hemodialysis. Semin Dial. 2011; 24(1):50-5. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011; 37(2):95-101. EUCAST. Rationale for the EUCAST clinical breakpoints, version 2.1. 2010. Accessed 6-11-2013.Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42 Suppl 1:S13-24. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download